{
  "docId": "019dd923-622c-750b-8b9a-4b91788fc785",
  "docSlug": "5fadb686cc03",
  "documentTitle": "Twist Bioscience (TWST)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2022-11-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2941177,
  "pageNumber": 176,
  "pageCount": 236,
  "prevPage": 175,
  "nextPage": 177,
  "slideType": "villain_critique",
  "function": "name_villain",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses direct quotes from a competitor to frame the target company's business model as unsustainable.",
  "elementsJson": [
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-4b91788fc785/176",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-4b91788fc785",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-4b91788fc785.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-4b91788fc785#slide-176",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Twist focuses on the worst, extreme commodity end of the DNA synthesis market; ongoing price war; no one has a differentiated offering; \"continue to be a commodity\"; Twist's market focus is \"not a successful strategy\"",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-0932-77cf-bff2-d6eaaffa356b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "paragraph",
      "text": "The executive characterized Twist as focusing on the worst, most commodity end of the DNA synthesis space – “not a successful strategy” – and described the price war ravaging the industry: “a lot of competition in the market”; “people expect the price to drop and drop, so we keep dropping it”; “we cannot charge a lot of money”; “we cannot say we are truly differentiated” – adding that he was being unusually honest.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9116b256-7be0-4716-9ffb-238bb9d07975",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.9,
        "x": 0.05,
        "y": 0.52
      },
      "kind": "quote",
      "text": "Twist focuses on the worst, extreme commodity end of the DNA synthesis market; ongoing price war; no one has a differentiated offering; “continue to be a commodity”; Twist’s market focus is “not a successful strategy”...",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "724754a1-99f6-4dc8-961e-c9d006f798df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"In terms of profit margin, it’s got to be one of the lowest. There’s a lot of competition in the market, and over time, people expect the price to drop and drop, so we keep dropping it. Relative to other types of more sophisticated services, we cannot charge a lot of money for that. We cannot say we are truly differentiated in gene synthesis. That’s not something that is conventional to say...I don’t think for gene synthesis, and I think we have gone past that time point where we can say that. So, I think going forward; it will probably continue to be a commodity. Just banking on the one service to make all of the profit is not a successful strategy at this point.\" — Executive at Genscript, key Twist competitor",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-0932-77cf-bff2-dbe1e8a76020",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c870c92-6406-41cf-93a4-9efa6fefbdfd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "An executive at Genscript, a publicly traded Chinese competitor, stated that the market is the worst of all worlds: a commodity in terms of pricing, but with a high cost to manufacture, adding that “price erosion” requires offering customers “something extra” to try and compete.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "73d2aec7-407d-4be8-a5d7-830963a42e80",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "antagonist-introduction",
      "slug": null,
      "matchId": "ee30fee5-8cf7-4433-9c64-5e8fee61d4d5",
      "evidence": "Uses competitor quotes to frame the subject company as failing.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}